Bendamustine is effective therapy in patients with rituximab‐refractory, indolent B‐cell non‐Hodgkin lymphomaBrad S. Kahl, Bruce D. Cheson, Nancy L. Bartlett et al.|Cancer|2009Cited by 246
Long‐term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non‐Hodgkin lymphomaPeter Martin, John P. Leonard, Zhengming Chen et al.|British Journal of Haematology|2017Cited by 33
Bendamustine Is Safe and Effective in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma.Brad S. Kahl, Bruce D. Cheson, Nancy L. Bartlett et al.|Blood|2007Cited by 15
Bendamustine HCl (TREANDATM) Treatment in Combination with Rituximab Results in Objective Responses in Patients with Refractory/Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin’s Lymphoma: Results from Phase II Multicenter Study (SDX-105-02).Katherine Robinson, Ely Benaim, Michael E. Williams et al.|Blood|2005Cited by 9
Long-Term Outcomes, Secondary Malignancies, and Stem Cell Collection Following Bendamustine in Patients with Previously Treated Indolent Non-Hodgkin LymphomaPeter Martin, John P. Leonard, Zhengming Chen et al.|Blood|2015Cited by 0